12:00 AM
May 07, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Pertuzumab: Phase III started

Chugai disclosed in its 1Q12 earnings presentation that in April it began a double-blind, placebo-controlled, international Phase III trial to compare IV pertuzumab plus Herceptin trastuzumab and standard chemotherapy vs. Herceptin plus standard chemotherapy in about 3,806 patients who had breast cancer surgery. Patients in the pertuzumab arm will receive an initial...

Read the full 247 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >